RIGEL PHARMACEUTICALS INC (RIGL)

US7665596034 - Common Stock

1.48  -0.01 (-0.67%)

After market: 1.49 +0.01 (+0.68%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

RIGEL PHARMACEUTICALS INC

NASDAQ:RIGL (3/28/2024, 8:00:02 PM)

After market: 1.49 +0.01 (+0.68%)

1.48

-0.01 (-0.67%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap259.56M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

RIGL Daily chart

Company Profile

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company is headquartered in South San Francisco, California and currently employs 155 full-time employees. The company went IPO on 2000-11-29. The firm is engaged in discovering, developing and providing therapies that improve the lives of patients with hematologic disorders and cancer. The firm's lead product, TAVALISSE (fostamatinib disodium hexahydrate) tablets, the spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Its product also includes REZLIDHIA (olutasidenib) capsules, which are for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. Its other clinical programs include its interleukin receptor-associated kinase (IRAK) inhibitor program and a receptor-interacting serine/threonine-protein kinase (RIPK1) inhibitor program in clinical development. In addition, it has product candidates in clinical development with partners BerGenBio ASA (BerGenBio) and Daiichi Sankyo (Daiichi).

Company Info

RIGEL PHARMACEUTICALS INC

611 Gateway Boulevard, Suite 900

South San Francisco CALIFORNIA 94080

P: 16506241100

CEO: Raul R. Rodriguez

Employees: 155

Website: https://www.rigel.com/

RIGL News

News Image7 days ago - Market News VideoCommit To Buy Rigel Pharmaceuticals At $1, Earn 20.1% Annualized Using Options
News Image17 days ago - Rigel Pharmaceuticals, Inc.Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer

/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, M.D. as Executive Vice President and Chief Medical...

News Image23 days ago - InvestorPlaceRIGL Stock Earnings: Rigel Pharmaceuticals Beats Revenue for Q4 2023

RIGL stock results show that Rigel Pharmaceuticals beat on revenue for the fourth quarter of 2023.

News Image23 days ago - BusinessInsiderRIGL Stock Earnings: Rigel Pharmaceuticals Beats Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rigel Pharmaceuticals (NASDAQ:RIGL) just reported results for the fourth quarte...

News Image24 days ago - Rigel Pharmaceuticals, Inc.Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and full year ended December 31, 2023,...

News Imagea month ago - AB NewswireRecent Market Movers: Healthcare Companies Making Headlines: DYAI, RIGL, ARDX, VERO, MEDS

RIGL Twits

Here you can normally see the latest stock twits on RIGL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example